Allogene Therapeutics Inc
Research Allogene Therapeutics Inc (ALLO) on Bullrun: market cap USD 504.20M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALLO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 504.20M
- Financial periodQ2 2026
- RevenueUSD 4.64M
- Net income-USD 42.68M
- Free cash flow-USD 32.15M
Valuation Snapshot
latest market cap is USD 504.20M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 190.89M | -USD 149.63M | n/a | -0.87 | USD 51.69M | USD 83.25M | USD 292.54M |
| FY2024 | USD 22.00K | -USD 257.59M | -USD 200.99M | n/a | -1.32 | USD 75.22M | USD 90.76M | USD 422.18M |
| FY2023 | USD 95.00K | -USD 327.27M | -USD 239.25M | n/a | -2.09 | USD 83.16M | USD 95.12M | USD 512.23M |
| FY2022 | USD 156.00K | -USD 340.41M | -USD 225.71M | n/a | -2.38 | USD 61.90M | USD 101.12M | USD 666.88M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 504.20M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 314.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 452.01M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 540.17M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 907.08M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.13B | n/a | n/a | n/a |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Allogene Therapeutics Inc's market cap?
Allogene Therapeutics Inc's market capitalization is USD 504.20M.
What does Allogene Therapeutics Inc do?
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL).